Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Thrombolytic Tx Cuts Mortality Rate With Pulmonary Embolism
However, risk of major bleeding, intracranial hemorrhage may be increased versus anticoagulation

TUESDAY, June 17, 2014 (HealthDay News) -- Among patients with pulmonary embolism, thrombolytic therapy is associated with lower rates of all-cause mortality but increased risks of major bleeding and intracranial hemorrhage (ICH) compared with anticoagulation therapy, according to research published in the June 18 issue of the Journal of the American Medical Association.

Saurav Chatterjee, M.D., from the St Luke's-Roosevelt Hospital Center of the Mount Sinai Health System in New York City, and colleagues conducted a literature review to identify randomized clinical trials comparing thrombolytic therapy versus anticoagulant therapy in pulmonary embolism patients. Of the 16 trials (2,115 individuals) identified, eight trials (1,775 patients) included patients with intermediate-risk pulmonary embolism.

The researchers found that use of thrombolytics was associated with lower all-cause mortality (odds ratio [OR], 0.53; 2.17 percent versus 3.89 percent with anticoagulants; number needed to treat [NNT], 59) and greater risks of major bleeding (OR, 2.73; 9.24 versus 3.42 percent; number needed to harm [NNH], 18) and ICH (OR, 4.63; 1.46 versus 0.19 percent; NNH, 78). In patients 65 years and younger, major bleeding was not significantly increased (OR, 1.25; 95 percent confidence interval, 0.50 to 3.14). There was a lower risk of recurrent pulmonary embolism associated with thrombolysis (OR, 0.40; NNT, 54). Thrombolysis was associated with lower mortality (OR, 0.48) and more major bleeding events (OR, 3.19) in intermediate-risk pulmonary embolism trials.

"Findings may not apply to patients with pulmonary embolism who are hemodynamically stable without right ventricular dysfunction," the authors write.

Several authors disclosed financial ties to the medical device industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)



Copyright © 2014 HealthDay. All rights reserved.

August 1, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Advanced Care Decision Aids Underutilized

Higher Risk of Vascular Events With Polymyalgia Rheumatica CME

CDC Issues Travel Warning As Africa Ebola Outbreak Worsens

Slow Progress Toward Meaningful Use Stage 2

FDA Approves Once-Daily, Long-Acting Inhaler for COPD

Jump in Doctor's Office Visits for Young Adults With Diabetes